Navigation Links
Avineuro Pharmaceuticals, Inc. Announces Beginning of Phase I Clinical Studies of AVN-211, Potent Small Molecule for Treatment of Schizophrenia.
Date:3/10/2009

SAN DIEGO, March 10 /PRNewswire/ -- Avineuro Pharmaceuticals, Inc. announced today an initiation of Phase I clinical studies of AVN-211, a potent and selective small molecule antagonist of 5-HT6 receptor for treatment of Schizophrenia. The results of Phase I studies are expected to be available in April 2009. Based on these and other results, Avineuro Pharmaceuticals, Inc. plans to advance AVN-211 into Phase II clinical trials in Q2 2009. Avineuro Pharmaceuticals, Inc. will present at the 9th International Conference - AD/PD 2009 - Prague, Czech Republic, March 11-15, 2009.

About Avineuro Pharmaceuticals, Inc.:

Avineuro discovers and develops novel small molecules for unmet medical needs in neurology and psychiatry. Avineuro emphasizes a rational approach to drug discovery that combines modern medicinal chemistry with streamlined pre-clinical and clinical development studies, thus allowing a fast transition to proof-of-concept product candidates.


'/>"/>
SOURCE Avineuro Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
3. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
4. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
5. Sucampo Pharmaceuticals, Inc. Begins Pivotal Phase III Studies of Oral Lubiprostone to Treat Opioid-Induced Bowel Dysfunction (OBD)
6. Symbollon Pharmaceuticals, Inc. Evaluates the Clinical Effects of IoGen(TM) on Fibrocystic Breast Disease
7. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
8. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
9. Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans
10. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
11. Solvay Pharmaceuticals, Inc. Responds to Advisory Committee Recommendation for Further Study of Tedisamil to Treat Atrial Fibrillation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... India , March 23, 2017 ... - 2021, a latest research report. The global vagus ... is shift of surgeons focus toward minimally invasive VNS ... or limited to few developed countries having high standards ... ...
(Date:3/22/2017)... Colo. , March 22, 2017 ... in the development of Ampion™, a low molecular ... properties, today announced that it is re-issuing its previous ... to incorporate certain disclosures that are required under ... 610(b). Included below are these additional disclosures along with ...
(Date:3/22/2017)... March 22, 2017  CANTEL MEDICAL CORP. (NYSE: ... President and CEO, will be presenting at the 16 th ... Grand Central Hotel in New York . ... at 3:00 p.m. ET. In addition, management will be available ... A live audio webcast will be available via the investor ...
Breaking Medicine Technology:
(Date:3/23/2017)... ... March 23, 2017 , ... Inflow IQ & Inflownomics of Raleigh, NC introduce ... a solid foundation. As experts in dangerous situations the Inflow IQ team can ... Inflownomics deliver ripe, fresh, clean & refreshing knowledge systems that enhance life. ...
(Date:3/23/2017)... FL (PRWEB) , ... March 23, 2017 , ... The ... that 2017 marks the 40th Anniversary of ABQAURP’s dedication to Health Care Quality and ... those who have contributed not only to the association, but also to the Health ...
(Date:3/23/2017)... ... March 23, 2017 , ... The founders of Dr. Wang ... winners of American Dreams & Good Housekeeping Seal Initiative, a nationwide search for ... Good Housekeeping. , Steven Wang, MD ., a renowned dermatologist and medical ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... New MEDDEV 2.7/1 Rev. 4 Guidance, **An FDAnews Webinar**, April 4, 2017 ... will the new EU MDR language change the way manufacturers approach CERs? ...
(Date:3/23/2017)... , ... March 23, 2017 , ... ... audit software solution, iCode Assurance, at HCCA’s 21st annual Compliance Institute on March ... the coding audit process for all medical chart types with a comprehensive set ...
Breaking Medicine News(10 mins):